• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

吸入伊洛前列素治疗毛细血管前肺动脉高压伴右侧心力衰竭患者。

Inhaled iloprost for patients with precapillary pulmonary hypertension and right-side heart failure.

机构信息

Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria.

出版信息

J Card Fail. 2011 Oct;17(10):813-8. doi: 10.1016/j.cardfail.2011.05.012. Epub 2011 Jul 8.

DOI:10.1016/j.cardfail.2011.05.012
PMID:21962419
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3190128/
Abstract

BACKGROUND

Pulmonary hypertension (PH) can lead to right-side heart failure (RHF) and death. There are no therapeutic recommendations for patients experiencing acute RHF in the course of PH. This study aimed to examine the safety and efficacy of inhaled iloprost in patients with precapillary PH and RHF.

METHODS AND RESULTS

Between October 2007 and December 2008, 7 patients with precapillary PH and RHF were enrolled. Per protocol, iloprost was inhaled hourly for a minimum of 12 hours during a 24-hour period. The starting dose of 2.5 μg was increased hourly by 2.5 μg as long as the increases were tolerated. Safety and efficacy were determined by continuous invasive monitoring of systemic and pulmonary hemodynamic parameters. Systemic pressures remained stable during inhalation (66.1 ± 6.9 mm Hg at baseline and 69.1 ± 6.4 mm Hg immediately after inhalation therapy, P = 0.48). Cardiac index increased from 2.4 ± 0.7 L/min/m(2) to 2.9 ± 0.9 L/min/m(2) (P = .008). Pulmonary vascular resistance decreased from 634.6 ± 218.3 dyn·s·cm(-5) to 489.6 ± 173.8 dyn·s·cm(-5) (P = .044), and N-terminal B-type natriuretic peptide levels decreased from 13,591 ± 10,939 pg/mL to 9,944 ± 8,569 pg/mL (P = .051).

CONCLUSION

Blood pressure-guided hourly inhalation of iloprost may offer a safe and effective strategy for the treatment of PH patients with RHF.

摘要

背景

肺动脉高压(PH)可导致右心衰竭(RHF)和死亡。对于 PH 过程中出现急性 RHF 的患者,目前尚无治疗建议。本研究旨在研究吸入伊洛前列素治疗毛细血管前 PH 和 RHF 患者的安全性和疗效。

方法和结果

2007 年 10 月至 2008 年 12 月,共纳入 7 例毛细血管前 PH 和 RHF 患者。根据方案,伊洛前列素以 2.5 μg/小时的起始剂量吸入,至少 12 小时,24 小时内每小时增加 2.5 μg,只要能够耐受增加的剂量。通过连续监测系统和肺血流动力学参数来确定安全性和疗效。吸入期间全身血压保持稳定(吸入前为 66.1 ± 6.9 mm Hg,吸入后即刻为 69.1 ± 6.4 mm Hg,P =.48)。心指数从 2.4 ± 0.7 L/min/m2增加至 2.9 ± 0.9 L/min/m2(P =.008)。肺血管阻力从 634.6 ± 218.3 dyn·s·cm-5降低至 489.6 ± 173.8 dyn·s·cm-5(P =.044),N 端 B 型利钠肽水平从 13,591 ± 10,939 pg/ml 降低至 9,944 ± 8,569 pg/ml(P =.051)。

结论

基于血压的伊洛前列素每小时吸入可能为 PH 合并 RHF 患者的治疗提供一种安全有效的策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9745/3190128/d1dbe337c76a/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9745/3190128/379bd8e0f915/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9745/3190128/ad21fdc2e384/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9745/3190128/d80db2294802/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9745/3190128/d1dbe337c76a/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9745/3190128/379bd8e0f915/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9745/3190128/ad21fdc2e384/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9745/3190128/d80db2294802/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9745/3190128/d1dbe337c76a/gr4.jpg

相似文献

1
Inhaled iloprost for patients with precapillary pulmonary hypertension and right-side heart failure.吸入伊洛前列素治疗毛细血管前肺动脉高压伴右侧心力衰竭患者。
J Card Fail. 2011 Oct;17(10):813-8. doi: 10.1016/j.cardfail.2011.05.012. Epub 2011 Jul 8.
2
Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost.重度原发性肺动脉高压(PPH)患者通过雾化吸入伊洛前列素实现循环休克的恢复。
Intensive Care Med. 1998 Jun;24(6):631-4. doi: 10.1007/s001340050628.
3
Hemodynamic effects of combination therapy with inhaled nitric oxide and iloprost in patients with pulmonary hypertension and right ventricular dysfunction after high-risk cardiac surgery.吸入一氧化氮和伊洛前列素联合治疗高危心脏手术后肺动脉高压伴右心功能障碍患者的血流动力学效应。
J Cardiothorac Vasc Anesth. 2013 Jun;27(3):459-66. doi: 10.1053/j.jvca.2012.07.020. Epub 2012 Oct 10.
4
Inhaled iloprost in eight heart transplant recipients presenting with post-bypass acute right ventricular dysfunction.吸入伊洛前列素治疗八例心脏移植受者体外循环后急性右心室功能障碍
Acta Anaesthesiol Scand. 2006 Nov;50(10):1213-7. doi: 10.1111/j.1399-6576.2006.01139.x. Epub 2006 Sep 15.
5
Evaluation of pulmonary vascular response to inhaled iloprost in heart transplant candidates with pulmonary venous hypertension.对患有肺静脉高压的心脏移植候选者吸入伊洛前列素后肺血管反应的评估。
Int J Cardiol. 2007 Jan 31;115(1):67-72. doi: 10.1016/j.ijcard.2006.01.067. Epub 2006 Jun 23.
6
Inhaled iloprost plus levosimendan to decompensate right heart failure due to chronic thromboembolic pulmonary hypertension.吸入伊洛前列素联合左西孟旦治疗慢性血栓栓塞性肺动脉高压所致右心衰竭失代偿期。
Anaesth Intensive Care. 2013 Jul;41(4):554-6.
7
Atrial natriuretic peptide in severe primary and nonprimary pulmonary hypertension: response to iloprost inhalation.严重原发性和非原发性肺动脉高压中的心房利钠肽:对吸入伊洛前列素的反应
J Am Coll Cardiol. 2001 Oct;38(4):1130-6. doi: 10.1016/s0735-1097(01)01490-5.
8
Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation.原发性肺动脉高压中血管舒张反应的评估。比较通过输注或吸入给予的前列环素和依洛前列素。
Eur Heart J. 2003 Feb;24(4):356-65. doi: 10.1016/s0195-668x(02)00302-0.
9
Hemodynamic effects of inhaled aerosolized iloprost and inhaled nitric oxide in heart transplant candidates with elevated pulmonary vascular resistance.吸入雾化伊洛前列素和吸入一氧化氮对肺血管阻力升高的心脏移植候选者的血流动力学影响。
Eur J Cardiothorac Surg. 2002 Nov;22(5):746-52. doi: 10.1016/s1010-7940(02)00488-8.
10
Inhaled iloprost to control pulmonary artery hypertension in patients undergoing mitral valve surgery: a prospective, randomized-controlled trial.吸入伊洛前列素用于控制二尖瓣手术患者的肺动脉高压:一项前瞻性随机对照试验。
Acta Anaesthesiol Scand. 2008 Jan;52(1):65-72. doi: 10.1111/j.1399-6576.2007.01476.x. Epub 2007 Nov 1.

引用本文的文献

1
Acute Iloprost Inhalation Improves Right Ventricle Function in Pulmonary Artery Hypertension: A Cardiac Magnetic Resonance Study.急性吸入伊洛前列素可改善肺动脉高压患者的右心室功能:一项心脏磁共振研究。
Front Pharmacol. 2019 Jan 21;9:1550. doi: 10.3389/fphar.2018.01550. eCollection 2018.
2
Acute hemodynamic effects of nebulized iloprost via the I-neb Adaptive Aerosol Delivery system in pulmonary hypertension.经 I-neb 自适应雾化输送系统雾化吸入伊洛前列素治疗肺动脉高压的急性血液动力学效应。
Pulm Circ. 2015 Mar;5(1):162-70. doi: 10.1086/679722.
3
An update on medical therapy for pulmonary arterial hypertension.

本文引用的文献

1
Intravenous epoprostenol versus high dose inhaled iloprost for long-term treatment of pulmonary hypertension.静脉注射依前列醇与高剂量吸入伊洛前列素治疗肺动脉高压的长期疗效比较。
Pulm Pharmacol Ther. 2011 Feb;24(1):169-73. doi: 10.1016/j.pupt.2010.06.004. Epub 2010 Jun 25.
2
Inhaled epoprostenol for the treatment of pulmonary arterial hypertension in critically ill adults.吸入前列环素治疗危重症成人肺动脉高压。
Pharmacotherapy. 2010 Jul;30(7):728-40. doi: 10.1592/phco.30.7.728.
3
The Adaptive Aerosol Delivery (AAD) technology: Past, present, and future.
肺动脉高压的医学治疗进展。
Curr Hypertens Rep. 2013 Dec;15(6):614-22. doi: 10.1007/s11906-013-0394-8.
自适应气溶胶输送(AAD)技术:过去、现在和未来。
J Aerosol Med Pulm Drug Deliv. 2010 Apr;23 Suppl 1(Suppl 1):S1-10. doi: 10.1089/jamp.2009.0791.
4
Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).肺动脉高压诊断和治疗指南:欧洲心脏病学会(ESC)和欧洲呼吸学会(ERS)肺动脉高压诊断和治疗工作组,得到国际心肺移植学会(ISHLT)认可。
Eur Heart J. 2009 Oct;30(20):2493-537. doi: 10.1093/eurheartj/ehp297. Epub 2009 Aug 27.
5
ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association.美国心脏病学会基金会专家共识文件工作组与美国心脏协会合作制定的2009年ACCF/AHA肺动脉高压专家共识文件,与美国胸科医师学会、美国胸科学会以及肺动脉高压协会共同完成。
J Am Coll Cardiol. 2009 Apr 28;53(17):1573-619. doi: 10.1016/j.jacc.2009.01.004.
6
A meta-analysis of randomized controlled trials in pulmonary arterial hypertension.一项关于肺动脉高压随机对照试验的荟萃分析。
Eur Heart J. 2009 Feb;30(4):394-403. doi: 10.1093/eurheartj/ehp022. Epub 2009 Jan 20.
7
Biochemistry of B-type natriuretic peptide--where are we now?B型利钠肽的生物化学——我们目前处于什么阶段?
Clin Chem Lab Med. 2008;46(11):1507-14. doi: 10.1515/CCLM.2008.295.
8
Prostacyclin therapies for the treatment of pulmonary arterial hypertension.用于治疗肺动脉高压的前列环素疗法。
Eur Respir J. 2008 Apr;31(4):891-901. doi: 10.1183/09031936.00097107.
9
Aerosolized iloprost for postoperative pulmonary hypertensive crisis in children with congenital heart disease.雾化吸入伊洛前列素治疗先天性心脏病术后肺动脉高压危象。
Int J Cardiol. 2008 Oct 13;129(3):333-8. doi: 10.1016/j.ijcard.2007.08.084. Epub 2007 Dec 21.
10
Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.在肺动脉高压患者中,将吸入伊洛前列素添加到现有波生坦治疗方案中的随机研究。
Am J Respir Crit Care Med. 2006 Dec 1;174(11):1257-63. doi: 10.1164/rccm.200603-358OC. Epub 2006 Aug 31.